Healthcare: Air Liquide Strengthens Its Position in Home Care for Patients with Diabetes & Participates in the French Artifi...
July 10 2017 - 11:49AM
Business Wire
Regulatory News:
By signing a partnership with CERITD, the French Center for
Studies and Research for the Intensification of Diabetes Treatment,
Air Liquide (Paris:AI) is strengthening its position in home
healthcare for patients with diabetes. Air Liquide also acquired an
equity stake in “Diabeloop”, the French start-up that is developing
an electronic artificial pancreas.
With this new collaboration, Air Liquide continues the approach
initiated by CERITD based on cooperation between hospital teams and
homecare nurses. At the request of physicians, nurses will be able
to help provide even more personalized follow-up for patients with
diabetes treated at home, such as adjusting the treatment in
accordance with a strict protocol.
In addition, to increase its level of expertise in the field of
diabetes and support innovation, Air Liquide has acquired an equity
stake via ALIAD, the Group’s venture capital investment arm,
in the French start-up Diabeloop, which is developing its
own artificial pancreas. Founded by CERITD’s diabetes
specialists, in partnership with the CEA Leti,1 Diabeloop is
designing an electronic artificial pancreas composed of an insulin
pump in the form of a patch and a glucose sensor both connected.
Driven by an algorithm, this system will enable to automate the
delivery of insulin and thus reproduce the functions of the
defective pancreas.
In practice, using the data collected by the continuous
glucose sensor, the algorithm determines the right dose of
insulin, which is then delivered in real time via the insulin
pump in order to improve patient glucose regulation.
This technology will help improve the daily life of patients
with type 1 diabetes by partially automating the
management of this disease. The investment made by Air Liquide in
Diabeloop confirms the Group’s commitment to digital
technologies and healthcare, in the aim of helping patients
achieve a better quality of life and care.
François Jackow, member of the Air Liquide group’s
Executive Committee, supervising the Healthcare activities, said:
"The partnership with CERITD, a leading research center for
diabetes treatment, and investments in innovative projects such as
Diabeloop's electronic artificial pancreas, are in line with the
development strategy of Air Liquide's Home Healthcare activity. By
relying on innovation ecosystems, Air Liquide is contributing
to advances in home care for patients with chronic
illnesses."
Air Liquide
HealthcareSupplies medical gases, home healthcare
services, hygiene products, medical equipment and specialty
ingredients.In 2016, it served over 15,000 hospitals and
clinics and more than 1.4 million patients at home
throughout the world. The Group’s Healthcare business reached
€3,111 million in revenues in 2016, with the support of its
15,000 employees.
The Home Healthcare Business of Air
LiquideAir Liquide, European leader in home
healthcare, provides home healthcare services in compliance
with medical prescription for patients suffering from chronic
diseases such as COPD (Chronic Obstructive Pulmonary Disease),
sleep apnea and diabetes. These home healthcare services are being
developed in addition to hospital care, enabling patients to enjoy
better quality of life and local authorities to reduce costs. Home
healthcare represents about 50% of Air Liquide's revenue in
Healthcare in 2016.
The world leader in gases, technologies and services for
Industry and Health, Air Liquide is present in 80 countries with
approximately 67,000 employees and serves more than 3 million
customers and patients. Oxygen, nitrogen and hydrogen are essential
small molecules for life, matter and energy. They embody Air
Liquide’s scientific territory and have been at the core of the
company’s activities since its creation in 1902.
Air Liquide’s ambition is to lead its industry, deliver long
term performance and contribute to sustainability. The company’s
customer-centric transformation strategy aims at profitable growth
over the long term. It relies on operational excellence, selective
investments, open innovation and a network organization implemented
by the Group worldwide. Through the commitment and inventiveness of
its people, Air Liquide leverages energy and environment
transition, changes in healthcare and digitization, and delivers
greater value to all its stakeholders.
Air Liquide’s revenue amounted to €18.1 billion in 2016 and its
solutions that protect life and the environment represented more
than 40% of sales. Air Liquide is listed on the Euronext Paris
stock exchange (compartment A) and belongs to the CAC 40, EURO
STOXX 50 and FTSE4Good indexes.
1 Electronics laboratory for information technology of the CEA
(The French Alternative Energies and Atomic Energy Commission)
www.airliquide.comFollow us on Twitter
@airliquidegroup
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170710005988/en/
Air LiquideCorporate CommunicationsCaroline
Brugier, +33 (0)1 40 62 50 59orAurélie Wayser-Langevin, +33 (0)1 40
62 56 19orInvestor RelationsParis+33 (0)1 40 62 50
87Radnor+1 (0) 610 263 8277orAir Liquide Healthcare
CommunicationsCoralie Gazzeri, +33(0)1 49 69 45 40
C3 AI (NYSE:AI)
Historical Stock Chart
From Mar 2024 to Apr 2024
C3 AI (NYSE:AI)
Historical Stock Chart
From Apr 2023 to Apr 2024